According to these findings, RP2 may be correlated with m6A modification in glioma, and the combined effect of METTL14, VIRMA, ALKBH5, YTHDC2 and METTL3 may eventually affect the progression and poor prognosis of glioma. This evidence concerns the gene ALKBH5 and central nervous system cancer.